Contact
searchSearch
HMP Global
Login

Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Craig Sauter, MD
Conference Coverage
Exploring CAR T-Cell Therapy for Aggressive Lymphomas Including DLBCL and CLL/SLL With Richter’s Transformation
10/18/2024
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia & Myeloma Congress, Craig Sauter, MD, discusses CAR T-cell therapy for R/R aggressive lymphomas such as chronic lymphocytic leukemia/small lymphocytic lymphoma with Richter’s transformation and diffuse large...
At the 2024 Lymphoma, Leukemia &...
10/18/2024
Oncology
Erin Wiedmeier-Nutor, MD
Videos
Targeted DNA Sequencing for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL
10/15/2024
Erin Wiedmeier-Nutor, MD, discusses study results that compare a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations with a fluorescence in situ hybridization panel among untreated patients...
Erin Wiedmeier-Nutor, MD, discusses study results that compare a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations with a fluorescence in situ hybridization panel among untreated patients...
Erin Wiedmeier-Nutor, MD,...
10/15/2024
Oncology
Kerry Rogers, MD
Conference Coverage
Should BTK Inhibitor Treatment be Discontinued Among Patients With CLL?
09/23/2024
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry Rogers, MD, participated in a debate in which she argued against discontinuing BTK inhibitor treatment among patients with chronic lymphocytic leukemia.
At the 2024 SOHO meeting, Kerry...
09/23/2024
Oncology
Talal Hilal, MD
Videos
Potential for Measurable Residual Disease as an End Point in Chronic Lymphocytic Leukemia Research
09/03/2024
Talal Hilal, MD, discusses an analysis on whether measurable residual disease can serve as a valuable end point in chronic lymphocytic leukemia clinical trials.
Talal Hilal, MD, discusses an analysis on whether measurable residual disease can serve as a valuable end point in chronic lymphocytic leukemia clinical trials.
Talal Hilal, MD, discusses an...
09/03/2024
Oncology
Matthew Davids, MD
Videos
Exciting Developments in Chronic Lymphocytic Leukemia Treatment Research
08/28/2024
Matthew Davids, MD, discusses groundbreaking developments in the chronic lymphocytic leukemia treatment landscape, focusing on the latest data from the ongoing AMPLIFY and MAJIC studies.
Matthew Davids, MD, discusses groundbreaking developments in the chronic lymphocytic leukemia treatment landscape, focusing on the latest data from the ongoing AMPLIFY and MAJIC studies.
Matthew Davids, MD, discusses...
08/28/2024
Oncology
Matthew Davids, MD
Videos
Acalabrutinib-Based Regimens Demonstrate Long-Term Benefits Among Higher-Risk Patients With CLL
08/28/2024
Matthew Davids, MD, discusses results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk chronic lymphocytic leukemia in treatment-naive or...
Matthew Davids, MD, discusses results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk chronic lymphocytic leukemia in treatment-naive or...
Matthew Davids, MD, discusses...
08/28/2024
Oncology
Talal Hilal, MD
Videos
Promising Developments in Chronic Lymphocytic Leukemia Treatment
08/20/2024
Talal Hilal, MD, discusses novel developments in the chronic lymphocytic leukemia treatment landscape, particularly a growing interest in utilizing measurable residual disease as an end point.
Talal Hilal, MD, discusses novel developments in the chronic lymphocytic leukemia treatment landscape, particularly a growing interest in utilizing measurable residual disease as an end point.
Talal Hilal, MD, discusses novel...
08/20/2024
Oncology
Nirav Shah, MD
Videos
Exploring New Therapies on the Horizon for Patients With R/R Chronic Lymphocytic Leukemia
08/09/2024
Nirav Shah, MD, shares insights into the research on exciting new therapies for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK degraders and cell therapies.
Nirav Shah, MD, shares insights into the research on exciting new therapies for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK degraders and cell therapies.
Nirav Shah, MD, shares insights...
08/09/2024
Oncology
John Allan, MD, Weill Cornell Medicine
Videos
How I Treat: An Older Patient With High-Risk CLL With Deletion 17p
07/15/2024
John Allan, MD, discusses the treatment regimen he chose for an older patient with high-risk chronic lymphocytic leukemia with deletion 17p who has chronic medical issues such as atrial fibrillation and diabetes.
John Allan, MD, discusses the treatment regimen he chose for an older patient with high-risk chronic lymphocytic leukemia with deletion 17p who has chronic medical issues such as atrial fibrillation and diabetes.
John Allan, MD, discusses the...
07/15/2024
Oncology
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use